Sotalol is a non-selective beta-adrenergic blocker with additional class III antiarrhythmic properties that prolong cardiac action potential duration by blocking potassium channels. It is used clinically to manage ventricular and supraventricular arrhythmias by reducing heart rate and stabilising cardiac rhythm. A key consideration is its potential to cause torsades de pointes due to QT interval prolongation, necessitating careful monitoring.